Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure

Journal of Cardiac Failure

Volumn 22, Issue 9, 2016, Pages 692-699

  Mansour, Ibrahim N ^a   Bress, Adam P ^a   Groo, Vicki ^a   Ismail, Sahar ^a   Wu, Grace ^a   Patel, Shitalben R ^a   Duarte, Julio D ^a   Kittles, Rick A ^a   Stamos, Thomas D ^a   Cavallari, Larisa H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

African American; fibrosis; Heart failure

Indexed keywords

PROCOLLAGEN; PROCOLLAGEN TYPE III N TERMINAL PEPTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; FEMALE; FOLLOW UP; GENE FREQUENCY; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; SEX DIFFERENCE; WEST AFRICAN; ACUTE DISEASE; AGE; ANALYSIS OF VARIANCE; BLOOD; CAUSE OF DEATH; COHORT ANALYSIS; ETHNOLOGY; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL ANALYSIS;

ACUTE DISEASE; ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BIOMARKERS; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84955455098     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.12.016     Document Type: Article

References (52)

1. 1 Alexander, M., Grumbach, K., Selby, J., Brown, A.F., Washington, E., Hospitalization for congestive heart failure. Explaining racial differences. JAMA 274 (1995), 1037–1042.
2. 2 Bahrami, H., Kronmal, R., Bluemke, D.A., Olson, J., Shea, S., Liu, K., et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med 168 (2008), 2138–2145.
3. 3 Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–322.
4. 4 Brown, D.W., Haldeman, G.A., Croft, J.B., Giles, W.H., Mensah, G.A., Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000. Am Heart J 150 (2005), 448–454.
5. 5 Dries, D.L., Exner, D.V., Gersh, B.J., Cooper, H.A., Carson, P.E., Domanski, M.J., Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 340 (1999), 609–616.
6. 6 Bibbins-Domingo, K., Pletcher, M.J., Lin, F., Vittinghoff, E., Gardin, J.M., Arynchyn, A., et al. Racial differences in incident heart failure among young adults. N Engl J Med 360 (2009), 1179–1190.
7. 7 Moe, G.W., Tu, J., Heart failure in the ethnic minorities. Curr Opin Cardiol 25 (2010), 124–130.
8. 8 Yancy, C.W., Heart failure in African Americans: a cardiovascular engima. J Card Fail 6 (2000), 183–186.
9. 9 Carson, P., Ziesche, S., Johnson, G., Cohn, J.N., Vasodilator–Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 5 (1999), 178–187.
10. 10 Exner, D.V., Dries, D.L., Domanski, M.J., Cohn, J.N., Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 (2001), 1351–1357.
11. 11 Vardeny, O., Cavallari, L.H., Claggett, B., Desai, A.S., Anand, I., Rossignol, P., et al. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail 6 (2013), 970–976.
12. 12 Swynghedauw, B., Molecular mechanisms of myocardial remodeling. Physiol Rev 79 (1999), 215–262.
13. 13 Brilla, C.G., Matsubara, L., Weber, K.T., Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 28 (1996), 269–275.
14. 14 Ramires, F.J., Mansur, A., Coelho, O., Maranhao, M., Gruppi, C.J., Mady, C., et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 85 (2000), 1207–1211.
15. 15 Zile, M.R., Baicu, C.F., Ikonomidis, J.S., Stroud, R.E., Nietert, P.J., Bradshaw, A.D., et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131 (2015), 1247–1259.
16. 16 Zannad, F., Alla, F., Dousset, B., Perez, A., Pitt, B., RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102 (2000), 2700–2706.
17. 17 Brilla, C.G., Funck, R.C., Rupp, H., Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 (2000), 1388–1393.
18. 18 Diez, J., Querejeta, R., Lopez, B., Gonzalez, A., Larman, M., Martinez Ubago, J.L., Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002), 2512–2517.
19. 19 SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
20. 20 Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J., Michelson, E.L., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003), 759–766.
21. 21 Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999), 709–717.
22. 22 Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003), 1309–1321.
23. 23 Tsutsui, H., Matsushima, S., Kinugawa, S., Ide, T., Inoue, N., Ohta, Y., et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res 30 (2007), 439–449.
24. 24 Koshy, S.K., Reddy, H.K., Shukla, H.H., Collagen cross-linking: new dimension to cardiac remodeling. Cardiovasc Res 57 (2003), 594–598.
25. 25 Diez, J., Laviades, C., Mayor, G., Gil, M.J., Monreal, I., Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 91 (1995), 1450–1456.
26. 26 Klappacher, G., Franzen, P., Haab, D., Mehrabi, M., Binder, M., Plesch, K., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995), 913–918.
27. 27 Lopez, B., Gonzalez, A., Ravassa, S., Beaumont, J., Moreno, M.U., San Jose, G., et al. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65 (2015), 2449–2456.
28. 28 Sato, A., Takane, H., Saruta, T., High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res 24 (2001), 99–104.
29. 29 Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr, Drazner, M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–239.
30. 30 Giri, V.N., Egleston, B., Ruth, K., Uzzo, R.G., Chen, D.Y., Buyyounouski, M., et al. Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev Res (Phila) 2 (2009), 244–250.
31. 31 Tian, C., Hinds, D.A., Shigeta, R., Kittles, R., Ballinger, D.G., Seldin, M.F., A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet 79 (2006), 640–649.
32. 32 Kosoy, R., Nassir, R., Tian, C., White, P.A., Butler, L.M., Silva, G., et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat 30 (2009), 69–78.
33. 33 Tsai, H.J., Choudhry, S., Naqvi, M., Rodriguez-Cintron, W., Burchard, EG, Ziv, E., Comparison of three methods to estimate genetic ancestry and control for stratification in genetic association studies among admixed populations. Hum Genet 118 (2005), 424–433.
34. 34 Falush, D., Stephens, M., Pritchard, J.K., Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 164 (2003), 1567–1587.
35. 35 Pritchard, J.K., Stephens, M., Donnelly, P., Inference of population structure using multilocus genotype data. Genetics 155 (2000), 945–959.
36. 36 Pencina, M.J., d'Agostino, R.B. Sr, d'Agostino, R.B. Jr, Vasan, R.S., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008), 157–172 discussion 207–112.
37. 37 Pocock, S.J., Wang, D., Pfeffer, M.A., Yusuf, S., McMurray, J.J., Swedberg, K.B., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27 (2006), 65–75.
38. 38 Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996), 1349–1355.
39. 39 CIBIS-II Investigators and Committees, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999), 9–13.
40. 40 MERIT-HF Study Group, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999), 2001–2007.
41. 41 Shindler, D.M., Kostis, J.B., Yusuf, S., Quinones, M.A., Pitt, B., Stewart, D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 77 (1996), 1017–1020.
42. 42 Radauceanu, A., Ducki, C., Virion, J.M., Rossignol, P., Mallat, Z., McMurray, J., et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 14 (2008), 467–474.
43. 43 Chan, V., Fenning, A., Hoey, A., Brown, L., Chronic beta-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat. J Cardiovasc Pharmacol 58 (2011), 424–431.
44. 44 Kobayashi, M., Machida, N., Mitsuishi, M., Yamane, Y., Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 17:12 Pt 1 (2004), 1112–1119.
45. 45 Le, D.E., Pascotto, M., Leong-Poi, H., Sari, I., Micari, A., Kaul, S., Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. Basic Res Cardiol, 108, 2013, 384.
46. 46 Sukumaran, V., Watanabe, K., Veeraveedu, P.T., Thandavarayan, R.A., Gurusamy, N., Ma, M., et al. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens Res 33 (2010), 695–702.
47. 47 Varagic, J., Ahmad, S., Voncannon, J.L., Moniwa, N., Simington, S.W. Jr, Brosnihan, B.K., et al. Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens 30 (2012), 1766–1774.
48. 48 Weber, K.T., Brilla, C.G., Campbell, S.E., Guarda, E., Zhou, G., Sriram, K., Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 88:Suppl 1 (1993), 107–124.
49. 49 Zannad, F., McMurray, J.J., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 (2011), 11–21.
50. 50 Krantz, M.J., Ambardekar, A.V., Kaltenbach, L., Hernandez, A.F., Heidenreich, P.A., Fonarow, G.C., Get With the Guidelines Steering Committee and Hospitals. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines–Heart Failure). Am J Cardiol 107 (2011), 1818–1823.
51. 51 Juurlink, D.N., Mamdani, M.M., Lee, D.S., Kopp, A., Austin, P.C., Laupacis, A., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004), 543–551.
52. 52 Rossignol, P., Dobre, D., McMurray, J.J., Swedberg, K., Krum, H., van Veldhuisen, D.J., et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 7 (2014), 51–58.